Purified anti-α-Synuclein, 103-108 Antibody -上海雅吉生物科技有限公司

规格	价格	库存
25µL	￥ 1344	1

Product Details

Verified Reactivity

Human

Antibody Type

Monoclonal

Host Species

Mouse

Immunogen

This antibody was developed using a purified, E. coli produced human α-synuclein.

Formulation

Phosphate-buffered solution (no preservatives or carrier proteins).

Preparation

The antibody was purified by affinity chromatography.

Concentration

1 mg/mL

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C. Please note the storage condition for this antibody has been changed from -20°C to between 2°C and 8°C. You can also check your vial or your CoA to find the most accurate storage condition for this antibody.

Application

IHC-P - Quality tested
WB - Verified
ELISA - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by formalin-fixed paraffin-embedded immunohistochemical staining. For immunohistochemistry, a concentration range of 1.0 - 2.5 ?g/mL?is suggested.?For Western blotting, the suggested use of this reagent is 1.0 - 10.0 ?g per mL. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

This antibody reacts with human a-synuclein. It does not react with mouse or rat a-synuclein. The epitope lies within amino acids 103-108 of a-synuclein.

Additional reported applications (for the relevant formats)?include: ELISA², Western blotting^1,2,3,4,6,8, and immunoprecipitation⁴.

Application References (PubMed link indicates BioLegend citation)

Lahut S, et al. 2017. Dis Model Mech. (WB)?PubMed
Landeck N, et al. 2016. Mol Neurodegener. 11(1): 61. (ELISA, WB)?PubMed
Moussaud S, et al. 2015. Expert Opin Ther Targets. 19(5): 589. (WB)?PubMed
Helferich AM., et al. 2015. Mol Neurodegener. 10(1): 66. (IHC, IP, WB)?PubMed
Bodis‐Wollner I, et al. 2014. Ann Neurol. 75(6): 964. (IHC)
Shen W, et al. 2014. J Neurochem. 129(5): 884. (WB)
Fagerqvist T, et al. 2013. J Neurochem. 126(1): 131. (IHC)
Ebrahimi-Fakhari D, et al. 2011. J Neurosci. 31(41): 14508. (WB)?PubMed
Welander H, et al. 2011. Biochem Biophys Res Commun. 412(1): 32. (IHC)

Product Citations

Schaser AJ, et al. 2019. Sci Rep. 9:10919. PubMed
Kiechle M, et al. 2019. Cell Reports. 29(9):2862-2874.e9. PubMed
Cariulo C, et al. 2019. Front Neurosci. 13:889. PubMed
Zhao J, et al. 2021. Acta Neuropathol. 142:807. PubMed
Butkovich LM, et al. 2020. J Neurosci. 7559:40. PubMed
Heras–Garvín A, et al. 2019. Mov Disord. 34:255. PubMed
Tanudjojo B, et al. 2021. Nat Commun. 12:3817. PubMed
Phan JA, et al. 2017. Sci Rep. 7:6363. PubMed
Scheiblich H, et al. 2021. Cell. 184:5089. PubMed
Van der Perren A, et al. 2020. Acta Neuropathol. 139:977. PubMed
Jiang P, et al. 2017. Sci Rep. 7:7690. PubMed
Zhao N, et al. 2020. Sci Transl Med. 12:00. PubMed

RRID

AB_2734561 (BioLegend Cat. No. 807804) AB_2564730 (BioLegend Cat. No. 807801) AB_2564731 (BioLegend Cat. No. 807802) AB_2564729 (BioLegend Cat. No. 807803)

Antigen Details

Structure

α-Synuclein’s canonical isoform is a 140 amino acid protein with an apparent molecular mass of 14 kD.

Distribution

Tissue distribution: Primarily nervous system, but lower expression in other tissues.
Cellular distribution: Cytoskeleton, cytosol, lysosome, mitochondria, nucleus, plasma membrane, and extracellular.

Biology Area

Cell Biology, Neurodegeneration, Neuroscience, Protein Misfolding and Aggregation

Molecular Family

α-Synuclein

Antigen References